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Mutants of Saccharomyces cerevisiae bearing lesions in the ergosterol 
biosynthetic pathway exhibit a pleiotropic drug-sensitive phenotype. This has 
been reported to result from an increased permeability of the membranes of 
the mutant strains to different drugs. As disruption of the yeast multidrug 
resistance protein, Pdr5p, results in a similar pleiotropic drug-sensitive 
phenotype, the possibility that Pdr5p may be functioning with a reduced 
efficiency in these altered sterol backgrounds was examined. To do this, the 
function of Pdr5p in isogenic strains of S. cerevisiae that have disruptions in 
the late stages of the ergosterol biosynthesis pathway (ERGG, ERG2, ERG3, 
ERG4) was studied. A reduced ability of Pdr5p to confer resistance to different 
drugs in these strains was observed, which did not appear to be dependent 
solely on the permeability of the membrane towards the drug. A simultaneous 
examination was made of how the lipid composition might be altering the 
efficiency of Pdr5p by similar studies in strains lacking phosphatidylserine 
synthase (encoded by CH09). The results indicated that the drug sensitivity 
of the erg strains is, to a significant extent, a result of the reduced efficiency 
of the Pdr5p efflux pump, and that the membrane environment plays an 
important role in determining the drug resistance conferred by Pdr5p. 
Keywords : Saccharornyces cerevisiae, multidrug resistance pump, membrane 
environment, sterols, erg mutants 
INTRODUCTION 
Multidrug resistance (MDR), the acquisition of sim- 
ultaneous resistance to a wide variety of structurally and 
functionally unrelated compounds, is often associated 
with the overexpression of one or  more members of a 
superfamily of ATP-binding cassette transporters 
(Gottesman & Pastan, 1993). These proteins are com- 
prised of 12 membrane-spanning a-helices and two 
ATP-binding domains (Borst & Schinkel, 1997). MDR 
is a ubiquitous phenomenon and the membrane proteins 
responsible for this phenomenon are conserved through- 
out the evolutionary scale. The mechanism by which 
these proteins are able to confer resistance to such a 
structurally diverse range of compounds is still not 
known (Gottesman et al., 1996). Structure-function 
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Abbreviations: DPH, diphenylhexatriene; TMA-DPH, trimethyl- 
ammonium diphenylhexatriene; MDR, multidrug resistance; P-gp, 
phosphoglycoprotein; wt, wild-type. 
analyses from different groups (Loo & Clarke, 1993; 
Beaudet & Gios, 1995; Hanna et al., 1996; Kwan & 
Gros, 1998) have not identified any single domain that is 
responsible for the diverse substrate specificity of MDR 
pumps, although mutations affecting substrate specifi- 
city appear to be clustered around the transmembrane 
domains and the substrates have been shown to bind 
within the membrane bilayer (Sharom, 1997). 
The yeast Saccharomyces cerevisiae has also been shown 
to contain a MDR efflux pump, PdrSp, that belongs to 
the family of ABC transporters. Pdr5p has been cloned 
independently by several groups (Bissinger & Kuchler, 
1994; Balzi et al., 1994; Hirata et al., 1994; Kralli et a/., 
1995) and has been shown to confer resistance to a wide 
range of compounds and metal ions (Mahe et al., 1996). 
Overproduction of this protein confers pleiotropic drug 
resistance, whilst disruption of the gene encoding it 
leads to a pleiotropic drug-sensitive phenotype. Recent 
work with PdrSp, however, could not identify any single 
domain that affects the substrate specificity of this pump 
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and it was suggested that the folded structure of the 
Pdr5p protein, and possibly the membrane composition, 
might play an important role in determining its substrate 
specificity (Egner et al., 1998). Yeast erg mutants, which 
carry mutations in the ergosterol biosynthetic pathway, 
are resistant to antifungal antibiotics that target this 
pathway, but are otherwise pleiotropically drug-sen- 
sitive to a wide variety of structurally diverse com- 
pounds. This has been reported to be due to an increased 
permeability of their membranes to different drugs (Bard 
et al., 1978). However, considering that disruption of 
the yeast PdrS pump also results in similar pleiotropic 
drug sensitvities, and the possible importance of the 
membrane environment in the functioning of these 
pumps, we decided to re-examine the drug-sensitive 
phenotypes of the erg mutants and investigate how the 
Pdr5 pump functions in these strains. An earlier investi- 
gation had repbrted that ergosterol, the major sterol of  
the yeast plasma membrane, inhibits the drug-binding 
ability of mammalian phosphoglycoproteins (P-gps) 
when expressed in yeast (Saeki et al., 1991); however, 
this has not been substantiated by later workers (Kuchler 
& Thorner, 1992). A possible role of lipids in the 
modulation of the drug-binding activity of P-gps has 
been suggested by the observations that many charac- 
teristics of P-gps, including the pattern of ATPase 
stimulation or inhibition by drugs, is affected by the 
lipid environment (Doige et al., 1993; Saeki et al., 1992; 
Urbatsch & Senior, 1995). 
Our results, described in this report, indicate that the 
membrane environment/composition plays a significant 
role in determining the functioning of MDR pumps, and 
that the drug sensitivity of erg mutants is, to a large 
extent, due to the decreased drug efflux mediated by 
PdrSp in these strains. 
METHODS 
Chemicals. The chemicals used were of analytical grade. All 
media components were either purchased from HiMedia or 
Difco. Rhodamine 6G, cycloheximide, crystal violet, emetine 
and p-oestradiol were obtained from Sigma. Diphenyl- 
hexatriene (DPH) and trimethylammonium diphenylhexa- 
triene (TMA-DPH) were obtained from Molecular Probes. 
Oligonucleotides were purchased from Ransom Hill Bio- 
sciences. Restriction/modification enzymes were obtained 
from New England Biolabs. 
Yeast strains, media and growth conditions. The yeast strains 
used in this study are listed in Table 1. They were grown at 
30 "C and maintained on yeast extract/peptone/dextrose 
medium (YPD). YPD and synthetic media (SD) were prepared 
as described by Rose e t  al. (1990). 
Stock solutions of crystal violet, cycloheximide and emetine 
were prepared in water, whilst rhodamine 6G and p-oestradiol 
solutions were made in ethanol. Plates containing different 
compounds were made by adding the required volume of the 
stock solution of the compound to YPD medium during 
pouring. 
Recombinant DNA methods. DNA manipulations including 
PCR were essentially carried out as described by Sambrook et 
al. (1989). Yeast genomic DNA was isolated by the glass bead 
lysis method (Rose et al., 1990). Yeast transformations were 
carried out by the lithium acetate method (Ito et al., 1983). 
Strain construction 
( I )  Construction of erg46 strain. Plasmid pCM2 containing the 
ERG4 gene disrupted with U R A 3  with flanking repeats 
(obtained from C. Marcireau, Rhone-Poulenc Rorer, Vitry- 
Sur-Seine, France) was cleaved with SacIIHpaI and the 6.94 kb 
erg4A : : U R A 3  fragment was transformed into strain ABC 709 
and selected for uracil prototrophy. The disruption at the 
ERG4 locus was confirmed by phenotypic analysis (drug 
sensitivity) and the U R A 3  region was popped out by selecting 
on 5-fluoroorotic acid plates, rendering erg4A a uracil auxo- 
troph. The disruptant strain thus obtained was crossed with 
strain ABC 710 and tetrads were dissected to obtain an erg4A 
ABC 283 strain in a protease-deficient background. 
(2) Construction of erg3A strain. The fragment containing 
erg3A::LEU2 was amplified from strain ABC 102 
(erg3A : : LEU2, obtained from L. Parks, North Carolina State 
University, Raleigh, USA) with the primers for the flanking 
regions of this fragment. Strain ABC 287 [constructed from a 
cross of ABC 229 and ABC 710, which was used as a wild-type 
(wt) strain] was transformed with the purified, 2.4 kb PCR 
product and selected for leucine prototrophy. The disruptant 
ABC 261 was confirmed by phenotypic characterization and 
PCR. 
(3) Construction of erg2A strain. The disruption of erg2A : : LEU2 
was done by introducing a 2.2 kb LEU2 gene at the NdeI site 
within the coding region of ERG2 in the plasmid pFLA 2-7 (the 
plasmid was obtained from J. Heinisch, Heinrich Heine 
Universjtat, Dusseldorf, Germany). A 3.2 kb StuI-PstI frag- 
ment containing the erg2A : : LEU2 construct was used to 
transform strain ABC 709 to leucine prototrophy. The strain 
was confirmed for the disruption at the right locus by 
phenotypic analysis and PCR. The disruptant was mated with 
strain ABC 710 and tetrad dissection was done to obtain an 
erg2A strain (ABC 271) in a protease-deficient background. 
(4) Construction of erg6A strain. An ERG6 (SED6) plasmid was 
obtained from H. Pelham, MRC, Cambridge, UK, and an 
ERG6 disruption was made by inserting a LEU2 fragment into 
the KpnI site of ERG6 that was first subcloned into the vector 
pGEX-2T. A 3.2 kb ScaI-BamHI fragment containing the 
erg6A: : LEU2 fragment was transformed into ABC 709 and 
selected for leucine prototrophy. The disruption at the ERG6 
locus was confirmed by PCR. An erg6A strain (ABC 265) in a 
protease-deficient background was obtained by crossing the 
resultant disruptant with ABC 710 and subsequently dissecting 
tetrads. 
(5) Construction of pdr5A strain. A diploid was made by crossing 
ABC 710 with ABC 152 (pdr5A: : TRPl) and a 3-2 kb ScaI- 
BamHI fragment of the plasmid bearing erg6A: : LEU2 was 
transformed into the diploid strain. The transformants were 
selected for leucine prototrophy and then plated on the 
sporulation medium. Tetrad dissection was done to obtain a 
pdr5A (ABC 288) strain in a protease-deficient background. 
(6) Construction of cholA strain. The chol A : : LEU2 strain was 
constructed by the PCR-mediated direct gene disruption 
method (Baudin et al., 1993). The primers CHDELl ( 5' 
AAGTTCGACTACGTCGTAAGGCCG 3') and CHDEL2 
AGTGGTAATGGAATCCCAACAATTACA 3') were used 
CACAGAGACGAAAATGACGGGTATGCCTCAGATG- 
(5' GACACAATATGCCATACCCAACACCAAAGCTAG- 
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Table 1. Yeast strains used in the present study 
Strain Genotype Source'" 
~- 
ABC 102 
(SY 12-D) 
(Y K I( A-7) 
(Y PH499) 
ABC IF2 
ABC 154 
ABC 229 
ABC 262 
ABC: 265 
ABC 2'1 
ABC 183 
ABC 1%' 
ABC 2 8  
ABC 625 
ABC 616 
ABC '06 
(BRS 1188) 
ABC 709 
(B JS4 18) 
ABC 710 
(B J54.58) 
M A T a  ura3-52 leu21 his4 erg3-12A::LEU 
M A T a  ura3-52 leu2A1 lys2-801 his3A200 ade2-101 t rp l  A63 
M A T a  ura3-52 leu2A1 lys2-801 his3A200 ade2-101 t r p l  A63 
stsl A : ; T R P l  
M A T a  ura3-52 leu2A1 lys2-801 his3A200 erg2A: : LEU2 
M A T a  ura3-52 leu2A1 lys2-801 his3A200 p e p 4 :  : HIS3 p r b l  A l . 6 R  
M A T a  ura3-52 leu2A1 lys2-801 his3A200 pep4 : : HIS p r b l  A1.6R 
M A T a  ura3-52 leu2A1 lys2-801 his3A200 p e p 4 :  ; HIS p r b l  A1.6R 
M A T a  ura3-52 leu2A.1 lys2-801 his3A200 p e p 4 :  : HIS3 p r b l  A1.6R 
M A T a  ura3-52 leu2A1 lys2-801 his36200 pep41 : HIS3 p r b l  A1.6R 
M A T a  ura3-52 leu2Al lys2-801 his3A200 p e p 4 :  : HIS3 p r b l  A1.6R 
M A T a  ura3-52 leu2A1 lvs2-801 his3A2OO ade2-101 t rp l  A63 
M A T a  ura3-52 leu2A1 lys2-801 his3A200 p e p 4 :  ; HIS3 p r b l  A1.6R 
M A T a  ura3-52 ade2-101 t rp lA63 chol A :  : T R P l  
canl erg3A::  LEU2 
canl  erg6A: : LEU2 
canl  erg2A::  LEU2 
canl  erg4A 
canl  
canl  p d r 5 A : :  T R P l  
chol A : T R P l  
canl  c h o l A : :  LEU2 
M A T a  ura3-52 leu2A1 lys2-801 his36200 
M A T a  ura3-52 leu2A1 lys2-801 his3A200 p e p 4 ;  : HIS3 p r b l  A1.6R 
canl  t rp lA63 
L. Parks 
K. Kuchler 
K. Kuchler 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
S. Henry 
E. Jones 
E. Jones 
"- L. Parks, North Carolina State University, Raleigh, USA; K. Kuchler, University and Biocenter of 
Vienna, Austria; S. Henry and E. Jones, Carnegie Mellon University, Pittsburgh, USA. 
for ma king the disruption. PCR was done from a LEU2-based 
plasmid, pSP1, and the 2.2 kb amplified product was used to 
transform ABC 287 strain to leucine prototrophy. The putative 
disruptant (leucine prototroph) (ABC 626) was checked for 
disruption by phenotypic analysis (choline auxotrophy) and 
PCR. 
To construct strain choZA: : TRPl in a background that was 
not protease-deficient, PCR was done on strain ABC 706 
(chol A :  : TRPI) with CHFOR (5' TCACATGGACCCATC- 
TAAAGA 3') and CHREV (5' TTTGACGCCAGGCAT- 
GAACAA 3') primers. The amplified product (2.6 kb) having 
c h o Z A :  : TRPl was used to  transform strain ABC 154 to 
tryptophan prototrophy.The disruption at the right locus was 
confirmed by phenotypic characterization and PCR in strain 
ABC 62.5. 
Construction of plasmid. The plasmid PDRS/YEplacl9.5 was 
constructed by digesting pSTSI (obtained from K. Kuchler, 
University and Biocenter of Vienna, Austria) with SphIIApaI, 
purifying the 7.5 kb  fragment and cloning in the SmaI site of 
the niulticopy plasmid YEplacl95 (Gietz & Sugino, 1988). 
In vivo drug sensitivity assay. PdrSp-mediated resistance to  
different compounds was tested by spotting serial dilutions of 
yeast culture onto plates containing drugs.The transformants 
were pregrown in SD broth lacking uracil to late-exponential 
phase and then reinoculated into fresh medium to a cell 
concentration of 5 x lo6 cells ml-'. After incubation for 6-7 h 
at 30 "C, the optical density was measured at  600 nm and the 
number of cells per ml of culture was calculated. Serial 
dilutions containing lo7, lo', lo5 and lo4 cells mlF' were then 
made in sterile water and 10 pl of each serially diluted culture 
was spotted onto YPD plates containing either the solvent or 
the drug, and onto SD lacking uracil (SD - ura) selection plates 
to check for plasmid stability. 
MIC estimations. The MIC of a drug was defined as the 
minimum concentration at which no growth was observed 
when 10 pl of the second dilution (i.e. 10, cells ml-') of a 
culture was spotted onto the plate containing the drug. 
Rhodamine 6G efflux assay in whole cells. The rhodamine 
efflux study was essentially carried out as described by 
Kolaczkowski e t  al. (1996) with a few modifications. The 
strains were pregrown in YPD broth for 12-14 h and then 
reinoculated into fresh media to  an initial OD,,, of 0.2. After 
incubation for 5-6 h at 30 "C, equal numbers of cells from an 
exponential-phase culture were harvested, washed four times 
with water and resuspended (wet wt = 40mg) in 0.5 ml 
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HEPES buffer (50 mM HEPES-NaOH, pH 7-0). 2-Deoxy-~-  
glucose and rhodamine 6G were added to a final concentration 
of 5 mM and 10 pM, respectively, and incubated at 25 "C for 
2 h. After incubation, rhodamine-6G-loaded cells were quickly 
spun down, washed twice with HEPES buffer and finally 
resuspended in 4 ml HEPES buffer. The final suspension was 
aliquoted into two parts (2 ml each), 1 mM glucose was added 
to one aliquot to initate the active, PdrSp-mediated efflux of 
rhodamine 6G. The cell suspension was incubated a t  room 
temperature. At time zero, i.e. immediately after the additioii 
of glucose, a 0.5 ml sample was withdrawn from both aliquots 
(with and without glucose), cells were quickly spun down and 
the fluorescence of rhodamine extruded in the assay buffer was 
measured at an excitation and emission wavelength of 529 nm 
and 553 nm, respectively (slit width = 5) on a Perkin-Elmer LS 
50 B spectrofluorimeter. After 7 and 21 min further incubation, 
a 0.5 ml sample was again withdrawn, cells were removed by 
centrifugation and the fluorescence of rhodamine 6G extruded 
in the supernatant was measured. 
Plasma membrane fluidity measurement. The fluidity of the 
yeast plasma membrane was measured in the whole cells using 
DPH and TMA-DPH as the fluorescent probes (Obrenovitch 
et af., 1978; Kuhry et af., 1985). The solutions of the probes 
were prepared in DMSO. Yeast cultures were grown overnight 
in YPD at 30 "C and then reinoculated into YPD at an OD,,, 
of approximately 0.24.3. After incubation for 5-6 h, cells 
were harvested, washed twice with sterile water and then 
suspended in buffer 1 (100 m M  sodium phosphate, 100 mM 
sodium chloride, 1 m M  EDTA, pH 7.4) to a density of 8 mg 
wet weight ml-'. The cells were incubated at 20 "C for 5 min 
and the DPH and TMA-DPH probes were added to a final 
concentration of 2 pM or 5 pM, respectively. The same volume 
of the solvent (DMSO) was added to the cells as a control. 
Incubation was continued for 20 min at 20 "C, after which the 
cells were immediately washed twice with buffer 1 and then 
suspended in the same volume of buffer 1. Fluorescence 
polarization was measured on a Perkin-Elmer LS 50 B 
spectrofluorimeter. The excitation and emission wavelengths 
were 360 nm and 450 nm, respectively. The measured 
fluorescence intensities were corrected for background 
fluorescence and light scattering from the unlabelled sample, 
i.e. the sample treated with the solvent alone. The degree of 
steady-state anisotropy ( rs )  was calculated as described by 
Haggerty et al. (1978) 
RESULTS 
Effect of Pdr5p overexpression on drug resistance in 
erg strains 
Strains with disruptions in the late steps of the ergosterol 
biosynthetic pathway are viable and accumulate sterols 
other than ergosterol in the membrane (Lees et al., 
1995). The predominant sterols that accummulate are 
the ones shown in Fig. 1. These strains have also been 
demonstrated to display an increased sensitivity to many 
drugs owing to an increased permeability of the mem- 
branes (Bard et al., 1978). We decided to examine if the 
yeast MDR protein, PdrSp, might be affected in the 
membranes with these different sterol contents. We 
constructed disruptions in the ERG6, ERG2, ERG3 and 
ERG4 genes as described in Methods. The strains were 
constructed in a vacuolar-protease-deficient (pep4 prbI ) 
background to minimize differences in the turnover 
rates of PdrSp; the turnover of PdrSp has been shown to 
Zymosterol 
& ERG6 
Fecosterol 
L ERG2 
Episterol 
4 ERG3 
Ergosta-5,7,24(28)-trienol 
$ ERG5 
Ergosta-5,7,22,24(28)-tetraenol 
L ERG4 
Ergosterol 
Fig. 1. Schematic representation of the late stages of  the 
ergosterol biosynthesis pathway from zymosterol t o  ergosterol. 
ERG6, ERG2, ERG3, E R G 5  and ERG4 encode S-adenosyl 
methionine methyltransferase, C-8 sterol isomerase, sterol A5 
desaturase, C-22 sterol desaturase and sterol-24(28) reductase, 
respectively. 
occur in the vacuole (Egner et al., 1995; Egner & 
Kuchler, 1996). 
PdrSp was overexpressed in different, erg strains by 
introducing the PDRS gene on a URA3-based multicopy 
plasmid, transforming the different erg strains with this 
plasmid, and then examining the resistance conferred to 
different drugs. We used drug resistance conferred by 
PdrSp overexpression in these strains as a means of 
evaluating PdrSp function. Overexpression of PdrSp 
itself did not affect the growth of the strains relative to 
the vector only, nor were there any differences in plasmid 
stability in the different strains (data not shown). 
We observed that all the erg strains showed an increased 
sensitivity to cycloheximide although to different extents 
(Fig. 2 ) .  Control experiments without drugs, or with 
only the solvents in which the drugs were dissolved, 
were carried out in these and subsequent experiments, to 
eliminate any differences that might have occurred in the 
absence of drugs (data not shown). As additional 
controls, the resistance conferred in wt and pdr5A strains 
was also simultaneously determined and these data are 
included in all the figures. The erg6A and erg4A strains 
were the most sensitive, and the sensitivity of the pdr5A 
strain was also comparable to that of the erg6A and 
erg4A strains. The sensitivities of the strains are a 
reflection of the intracellular accumulation of the drug 
under steady-state conditions. When we overexpressed 
PdrSp in these strains, we found that overexpression of 
the PdrSp in these different strains did not lead to drug 
resistance to the same levels (Fig. 2). PdrSp over- 
expression led to significantly higher levels of drug 
resistance in the erg46 strain as compared to the erg6A 
strain, and even as compared to the erg2A strain, which 
otherwise displayed lesser sensitivity. In the pdr5A 
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Cycl o hexi m id e 
(ng m1-l): 10 25 35 50 65 80 100 200 300 500 750 1000 
Plasmid: U P U P U P U P U  P U P V P U P U P U P  U P V P 
------------
. . . . . . . . . . . . . . . . . . . . . . . . . , , . . . , , . . . . . . . . . . . . . . , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . , , . . , . , , , . . . . , . 
Fig. 2. Pdr5p-mediated cycloheximide resistance in wt, erg4A, erg3A, erg2A, erg6A and pdr5A strains of 5. cerevisiae. 
Strains transformed either with the control plasmid YEplacl95 (U) or with the PDR5-overexpressing plasmid 
PDR5NEplac195 (P) were grown to exponential phase in SD-ura a t  30°C. An equal number of cells of each strain was 
harvested, resuspended in sterile water to a density of 1 x l o 7  cells ml-' and 10 pl of undiluted cell suspension, 1 : 10, 
1 : 100 and 1 : 1000 dilutions was spotted onto YPD plates containing different concentrations of cycloheximide. Growth 
was scored after 3 d incubation a t  30 "C. The growth pattern of the first two suspensions (lo7 and l o 6  cells ml-I) is shown 
in the first and second rows, respectively. 
strain, however, which otherwise has no altered sterols 
in the membrane, the level of resistance conferred was 
up to the wt levels. These results indicate firstly that 
alteration in the sterol content of the cells led to a 
decreased drug resistance conferred by PdrSp as com- 
pared to the cells having ergosterol in their membranes, 
and secondly that the decreased resistance was not a 
simple consequence of increased permeability and sen- 
sitivity of the strains to the drug. 
To exiimine whether our observation with cyclo- 
heximide was a general phenomenon, we extended this 
study to other structurally unrelated drugs, crystal 
violet, emetine and oestradiol. The conclusions we 
reached with crystal violet (data not shown), were very 
similar to those with cycloheximide. In the case of 
emetine, however, PdrSp virtually failed to confer any 
significant resistance in erg6A and erg2A strain back- 
grounds (Fig. 3 ) ,  although it could mediate efflux of the 
drug in  the other strain backgrounds. The results with 
oestradiol were interesting in that we were able to 
observe oestradiol toxicity for the first time in yeast 
using the erg6A strain. However, we observed that 
oestradiol toxicity could be effectively reversed even in 
an erg6A background by PdrSp overexpression (Fig. 4), 
indicating that PdrSp was functioning in this back- 
ground to efflux some, but not all of the drugs. 
Rhodamine 6G efflux in ergosterol-deficient strains 
of S. cerevisiae 
Since the decreased drug resistance conferred by PdrSp 
was indirect evidence of PdrSp efficiency under steady- 
state conditions, we decided to measure PdrSp efficiency 
directly by monitoring the PdrSp-mediated efflux of 
rhodamine 6G in erg backgrounds at different time 
intervals. 
Rhodamine 6G is a known substrate of PdrSp and is 
reported to be effluxed by PdrSp in an energy-dependent 
manner (Kolaczkowski et al., 1996). T o  check the 
functioning of PdrSp in altered sterol backgrounds, we 
carried out the rhodamine efflux assay in erg strains 
along with the wt and p d r 5 A  strains serving as the 
positive and negative controls. The energy-dependent 
PdrSp-driven extrusion of rhodamine was initiated by 
the addition of 1 m M  glucose and fluorescence of 
extruded dye in the assay buffer was measured after 
different time intervals. The erg4A,  e r g 2 A  and erg6A 
strains were found to efflux rhodamine 6G at a slower 
rate than the wt cells while e r g 3 A  cells showed a 
relatively higher rate of efflux as compared to other erg 
strains (Table 2). Rhodamine efflux was seen in the wt, 
e r g 4 A  and e r g 3 A  strains 7 min after glucose addition; 
however, very little efflux was seen in erg2A and erg6A 
strains after 7 min. We also examined the efflux after 
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Emetine Oestrad iol 
Plasmid: V P V  P V P V P V P V  P V P V  P Plasmid: V P  V P V  P 
(pg mi-’): 75 150 225 --- (Pgml-’): 50 100 200 300 500 750 1000 2000 --------
.............................................. . .... ... ..... . .......... ...... .............. . ..... I ................. ..................... ...... ...... 
Fig. 3. Pdr5p-mediated emetine resistance in wt, erg4A, erg3A, 
erg2A, erg6A and pdr5A strains of 5. cerevisiae. The experiment 
was essentially done as described in Methods and in the legend 
to Fig. 2. V, control plasmid; P, PDRS-overexpressing plasmid. 
21 min. At this time point, both erg2A and erg6A cells 
were found to be able to efflux rhodamine in the 
presence of glucose. Very little release of rhodamine was 
seen at  21 min in the erg2A and erg66 mutants in the 
absence of glucose indicating that efflux was not due to 
mere leakage of the dye across the membranes. The cells 
lacking PdrSp (pdr5A strain) showed very low levels of 
active efflux of the dye even 21 min after glucose addition 
(Table 2). This experiment demonstrated that although 
PdrSp was functional in these strains, the altered sterol 
environment had a significant effect on its efflux 
capabilities. 
Does Pdr5p function in erg strains correlate with 
membrane fluidity? 
Alteration in sterol content of the membrane is known 
to primarily affect its fluidity. T o  determine whether the 
differences in PdrSp efficiency that we observed in 
different strains was correlated with membrane fluidity, 
we measured the membrane fluidity of the strains. This 
was done with whole cells using both DPH and TMA- 
DPH as probes. The fluorescence anisotropies of these 
probes in membranes correlate inversely with membrane 
fluidity. Although we did observe an increase in mem- 
brane fluidity in erg mutants relative to the wt, we could 
not find any correlations between the membrane fluidity 
of these strains and the efficiency of the PdrSp pump 
(Table 3). 
Fig. 4. Pdr5p-mediated /?-oestradiol resistance in wt, erg46, 
erg3A, erg2A, erg6A and pdr5A strains of S. cerevisiae. The 
experiment was essentially done as described in Methods and in 
the legend to Fig. 2. V, control plasmid; P, PDR5overexpressing 
plasmid. 
Pdr5p pump efficiency in a phosphatidylserine- 
deficient mutant 
As alteration of the sterol composition led to a significant 
reduction in the ability of PdrSp to  confer drug 
resistance, we wished to determine if alteration in the 
phospholipid composition of the membrane might also 
affect PdrSp efficiency. We therefore constructed a chol A 
strain in the same background. These cells are choline 
auxotrophs but are otherwise viable. CHOl encodes 
phosphatidylserine synthase and its disruption results in 
the membrane being completely devoid of phosphatidyl- 
serine (Hikiji et al., 1988). The lack of phosphatidyl- 
serine is largely compensated for by an increase in the 
phosphatidylinositol and phosphatidylcholine levels 
(Atkinson et al., 1980). 
When we overexpressed PdrSp from a multicopy 
plasmid in such a cholA strain in a similar manner to 
that done for erg mutants, we observed that the plasmid 
bearing PDRS was highly unstable, making a com- 
parison of the drug resistance profiles of PdrSp difficult 
to study (data not shown). We therefore carried out the 
~ 
Table 2. Pdr5p-mediated energy-dependent efflux of 
rhodamine 6G in wt, erg4A, erg3A,erg2AI erg66 and 
pdr5A strains of 5. cerevisiae 
.................. ................................................................. t ........................................................ 
Cells were harvested, prepared and loaded with rhodamine 6G 
as described in Methods. Rhodamine 6G efflux was initated by 
adding I rnM glucose. The experiment was repeated twice and 
the values given are of a representative experiment. 
Strains Rhodamine 6G fluorescence intensity 
at (min) : 
wt - gluiose 
wt + glucose 
erg4A - glucose 
erg4A +glucose 
erg3A - glucose 
erg3A + glucose 
erg2A -glucose 
erg2A + glucose 
erg6A - glucose 
erg6A + glucose 
pdr5A -glucose 
pdr5A + glucose 
0 7 21 
112 
123 
114 
116 
119 
134 
121 
107 
120 
120 
120 
114 
143 
473 
133 
245 
133 
358 
151 
158 
142 
170 
152 
147 
170 
795 
143 
226 
147 
608 
172 
352 
154 
290 
174 
200 
Table 3. Fluorescence anisotropies of DPH and TMA- 
DPH in wt, erg4A, erg3A, erg2A and erg6A strains of S. 
cere visia e 
hleasurements were carried out on whole cells and fluorescence 
anisotropy values were calculated as described in Methods. The 
values represent the mean of three experiments f SD (each 
experiment was done in triplicate). 
Strain DPH TMA-DPH 
~ 
wt 0.388 f 0-056 0.561 f 0-055 
erg4A 0,346 f 0-032 0.559 f 0.042 
erg3A 0.29 1 & 0.009 0.490 f 0.020 
e rg2 A 0.300 f 0.012 0-505 f 0.030 
erg6A 0.344 f 0.020 0-5 13 f 0.024 
analysis in a strain that is not deficient in the vacuolar 
proteases PEP4 and PRBl. In this background, the 
plasmid was stable, which allowed the comparison of 
Pdr5p oirerexpression in this strain (Fig. 5). 
The cho 1A strain was mildly resistant to cycloheximide 
as compared to the wt strain, as seen in Fig. 5. Pdr5p 
overexpression in the c h o l A  strain was, though, able to 
confer resistance to cycloheximide to a significant level ; 
however, it did not reach the wt levels of resistance. 
In the case of crystal violet, the cholA strain was 
significantly more resistant as compared to the wt cells, 
S. cerevisiae multidrug resistance pump modulation 
- -  wt cho 1 A 
Plasmid: V P V P 
E 
t 
500 
700 
1000 
Fig- 5. Stability of PDRS-overexpressing plasmid in wt (ABC154) 
and cholA (ABC625) strains of S. cerevisiae. wt and cholA 
strains were transformed with either the control plasmid 
YEplacl95 (V) or the PDRS-overexpressing plasmid 
PDRSREplacl95 (P). The wt transformants and the cholA 
transformants were grown to exponential phase in SD-ura 
broth and SD-ura broth supplemented with 1mM choline, 
repsectively. Cells were spotted onto plates of YPD, SD-ura 
containing 1 mM choline, and YPD containing different 
concentrations of cycloheximide as described in the legend to 
Fig. 2. The growth pattern of the first two suspensions ( lo7 and 
lo6  cells ml-') is shown in the first and second rows, 
respective I y. 
and the level of resistance conferred by Pdr5p was also 
significantly higher than that in the wt strain (Fig. 6). 
This drug selectivity indicates that lipid composition 
also plays a role in modulating the level of drug 
resistance conferred by the PdrSp pump, and in a drug- 
specific manner. 
DISCUSSION 
In this report, we have investigated whether the pleio- 
tropic drug sensitivity of erg mutants might in part result 
from an altered functioning of the yeast MDR pump, 
PdrSp. These erg strains are used extensively in different 
drug-based studies (Graham et al., 1993; Hemenway & 
Heitman, 1996) and the tacit assumption has been that 
these strains are hyperpermeable to different drugs. 
However, the studies described in this report indicate 
that this assumption is not entirely valid and one also 
has to take into account the fact that the efflux pumps 
have a reduced efficiency in these backgrounds. We have 
not examined the localization of Pdr5p in these strains 
and it is possible that the reduced efficiency of Pdr5p in 
~ 
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wt cho 1 A 
Plasmid: V P V P  
Fig. 6. Pdr5p-mediated crystal violet resistance in wt and cholA 
(ABC 625) strains of S. cerevisiae. The experiment was 
essentially done as described in Methods and in the legend to 
Fig. 5. V, control plasmid; P, PDRS-overexpressing plasmid. 
altered sterol backgrounds could be due to partial 
mislocalization of the protein. However, complete 
mislocalization had not ocurred since the pumps could 
mediate efflux of some of the drugs, although to lesser 
extents. Some other important conclusions may be 
drawn from this study. Firstly, the drug resistance 
profiles were affected in a manner that was dependent on 
both the strain background and the drug being tested. 
Thus the erg6A strain could efflux some, but not all, of 
the drugs. This suggests that although the lipid bilayer is 
not the primary determinant for substrate specificity, it 
plays an important role in modulating this specificity in 
addition to modulating efficiency. Furthermore, pre- 
vious studies have indicated that the ability of the MDR 
pump to mediate efflux of a drug depends on the 
permeability of the membrane to the drug (Eytan et al., 
1996, 1997), but we observed that the reduced ability of 
PdrSp to efflux drugs in different strains is not dependent 
solely on the permeability of the membrane towards the 
drugs. 
Our results also highlight the importance of evaluating 
the function and substrate specificity of MDR pumps 
over a range of drug concentrations to attain more 
complete resistance profiles. 
The decreased efflux of drugs in the erg6A strain leading 
to the drug hypersensitivity phenotype is in contrast to 
the cation-sensitivity phenotype of this strain, where the 
Lit and Na' hypersensitivity was primarily due to 
increased uptake rather than the decreased efflux 
(Welihinda et al., 1994). erg6A cells also exhibit defective 
tryptophan uptake, presumably due to a defect in 
tryptophan permease (Caber et al., 1989). In addition to 
this, the transport kinetics of a few other permeases of 
yeast is also known to be affected by the lipid com- 
position of the membrane (Keenan et al., 1982; 
Calderbank et al., 1985). 
Recently, Egner et al. (1998) have initated detailed 
studies of mutants of PdrSp with altered function by 
random mutagenesis. As mutants with altered substrate 
specificity were observed to occur in no single domains, 
and a few of the mutants were also found to have defects 
in folding, these authors have suggested a possible role 
for the folded structure of PdrSp as a major determinant 
of its diverse substrate specificity. Lipids have been 
shown to function as molecular chaperones (Bogdanov 
et al., 1996) and it is possible that in strains with altered 
lipid/ergosterol content, some defect in folding of 
membrane proteins may occur and that this might be 
partly responsible for both their altered efficiency and 
their altered substrate specificity. 
The observation that PdrSp overexpression in a 
phosphatidylserine-deficient mutant in a protease- 
deficient background led to significant differences in 
plasmid stability suggests that overexpression of this 
protein is, for some reason, deleterious to cells in this 
background. Mammalian P-gps have also been shown to 
destabilize membranes (Arsenault et al., 1988) and it 
may be interesting to examine whether the 
destabilization is affected by the composition of the 
membrane itself. 
The present study, for the first time, reports that the 
reduced efficiency of the MDR pump, PdrSp, in S. 
cerevisiae erg strains is responsible to a significant extent 
for their pleiotropic drug-sensitive phenotypes. This 
observation is of great significance in view of the fact 
that the majority of antifungal compounds that are 
being extensively used to treat fungal infections inhibit 
the enzymes of the ergosterol biosynthetic pathway. 
Thus it will be very interesting to study whether the 
reduced efficiency of the MDR pumps of these yeasts 
might allow use of other drugs in combating the fungal 
infection. The present study, if extended to pathogenic 
yeast-like Candida spp., may shed some light on the 
complex drug resistance phenomenon of this yeast, and 
will stimulate further dissection of the role of the 
membrane in the functioning of MDR pumps. 
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